Wall Street analysts expect that ICU Medical, Inc. (NASDAQ:ICUI) will report sales of $321.44 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for ICU Medical’s earnings. The highest sales estimate is $329.48 million and the lowest is $313.40 million. ICU Medical posted sales of $96.72 million during the same quarter last year, which would indicate a positive year over year growth rate of 232.3%. The company is scheduled to announce its next earnings results on Monday, August 14th.

According to Zacks, analysts expect that ICU Medical will report full year sales of $321.44 million for the current year, with estimates ranging from $1.23 billion to $1.25 billion. For the next year, analysts forecast that the firm will post sales of $1.33 billion per share, with estimates ranging from $1.32 billion to $1.34 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow ICU Medical.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $1.23. The firm had revenue of $247.74 million during the quarter, compared to the consensus estimate of $237.12 million. ICU Medical had a return on equity of 9.63% and a net margin of 18.76%. The firm’s quarterly revenue was up 175.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.26 EPS.

A number of research analysts have weighed in on ICUI shares. Zacks Investment Research lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Monday, March 13th. Roth Capital lowered shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Thursday, May 11th. They noted that the move was a valuation call. BidaskClub raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Sidoti lowered shares of ICU Medical from a “buy” rating to a “neutral” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $142.50.

TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/21/analysts-expect-icu-medical-inc-icui-will-post-quarterly-sales-of-321-44-million.html.

In other ICU Medical news, Director Joseph R. Saucedo sold 4,500 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $162.51, for a total transaction of $731,295.00. Following the completion of the transaction, the director now owns 3,091 shares of the company’s stock, valued at approximately $502,318.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Alison D. Burcar sold 18,290 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $160.72, for a total transaction of $2,939,568.80. Following the transaction, the vice president now directly owns 3,727 shares of the company’s stock, valued at approximately $599,003.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,384 shares of company stock valued at $3,766,450. Company insiders own 15.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in ICU Medical by 87,088.7% in the first quarter. BlackRock Inc. now owns 1,769,930 shares of the medical instruments supplier’s stock worth $270,268,000 after buying an additional 1,767,900 shares in the last quarter. Janus Capital Management LLC raised its position in ICU Medical by 178.8% in the first quarter. Janus Capital Management LLC now owns 1,439,864 shares of the medical instruments supplier’s stock worth $219,864,000 after buying an additional 923,395 shares in the last quarter. Wellington Management Group LLP raised its position in ICU Medical by 12.1% in the first quarter. Wellington Management Group LLP now owns 652,897 shares of the medical instruments supplier’s stock worth $99,697,000 after buying an additional 70,283 shares in the last quarter. Champlain Investment Partners LLC raised its position in ICU Medical by 4.6% in the first quarter. Champlain Investment Partners LLC now owns 496,220 shares of the medical instruments supplier’s stock worth $75,773,000 after buying an additional 21,630 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in ICU Medical by 29.3% in the first quarter. Wells Fargo & Company MN now owns 465,840 shares of the medical instruments supplier’s stock worth $71,133,000 after buying an additional 105,570 shares in the last quarter. 77.95% of the stock is owned by hedge funds and other institutional investors.

Shares of ICU Medical (ICUI) opened at 169.50 on Wednesday. ICU Medical has a 52 week low of $103.65 and a 52 week high of $175.73. The stock’s 50 day moving average price is $163.34 and its 200 day moving average price is $151.41. The firm has a market capitalization of $3.36 billion, a P/E ratio of 30.13 and a beta of 0.38.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.